Cargando…

Anticancer Therapeutic Strategies Targeting p53 Aggregation

p53 is a tumor suppressor protein that is mutated in more than 50% of cancer cases. When mutated, it frequently results in p53 oncogenic gain of function (GOF), resulting in a greater tendency to aggregate in the phase separation and phase transition pathway. GOFs related to p53 aggregation include...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ferretti, Giulia D. S., Quarti, Julia, dos Santos, Gileno, Rangel, Luciana P., Silva, Jerson L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9569952/ https://www.ncbi.nlm.nih.gov/pubmed/36232329 http://dx.doi.org/10.3390/ijms231911023

Ejemplares similares

Loss of the p53 transactivation domain results in high amyloid aggregation of the Δ40p53 isoform in endometrial carcinoma cells
por: Melo dos Santos, Nataly, et al.
Publicado: (2019)

The aggregation of mutant p53 produces prion-like properties in cancer
por: Rangel, Luciana P, et al.
Publicado: (2014)

Misfolding, Aggregation, and Disordered Segments in c-Abl and p53 in Human Cancer
por: de Oliveira, Guilherme A. P., et al.
Publicado: (2015)

Phase separation of p53 precedes aggregation and is affected by oncogenic mutations and ligands
por: Petronilho, Elaine C., et al.
Publicado: (2021)

PRIMA-1 inhibits Y220C p53 amyloid aggregation and synergizes with cisplatin in hepatocellular carcinoma
por: Paz, Mariana M., et al.
Publicado: (2023)

Resveratrol prevents p53 aggregation in vitro and in breast cancer cells
por: Ferraz da Costa, Danielly C., et al.
Publicado: (2018)

Expanding the prion concept to cancer biology: dominant-negative effect of aggregates of mutant p53 tumour suppressor
por: Silva, Jerson L., et al.
Publicado: (2013)

Transient Transfection of a Wild-Type p53 Gene Triggers Resveratrol-Induced Apoptosis in Cancer Cells
por: Ferraz da Costa, Danielly Cristiny, et al.
Publicado: (2012)

Recent Synthetic Approaches towards Small Molecule Reactivators of p53
por: Silva, Jerson L., et al.
Publicado: (2020)

Anticancer Potential of Resveratrol, β-Lapachone and Their Analogues
por: Ferraz da Costa, Danielly C., et al.
Publicado: (2020)

Bioactive Compounds and Metabolites from Grapes and Red Wine in Breast Cancer Chemoprevention and Therapy
por: Ferraz da Costa, Danielly C., et al.
Publicado: (2020)

The Status of p53 Oligomeric and Aggregation States in Cancer
por: de Oliveira, Guilherme A. P., et al.
Publicado: (2020)

Aggregation tendencies in the p53 family are modulated by backbone hydrogen bonds
por: Cino, Elio A., et al.
Publicado: (2016)

Mutant p53 Aggregates into Prion-like Amyloid Oligomers and Fibrils: IMPLICATIONS FOR CANCER
por: Ano Bom, Ana P. D., et al.
Publicado: (2012)

Aggregation-primed molten globule conformers of the p53 core domain provide potential tools for studying p53C aggregation in cancer
por: Pedrote, Murilo M., et al.
Publicado: (2018)

Cancer Chemoprevention by Resveratrol: The p53 Tumor Suppressor Protein as a Promising Molecular Target
por: Ferraz da Costa, Danielly C., et al.
Publicado: (2017)

p53 Aggregates Penetrate Cells and Induce the Co-Aggregation of Intracellular p53
por: Forget, Karolyn J., et al.
Publicado: (2013)

Therapeutic Strategies to Activate p53
por: Aguilar, Angelo, et al.
Publicado: (2022)

Oncogenic Gain of Function in Glioblastoma Is Linked to Mutant p53 Amyloid Oligomers
por: Pedrote, Murilo M., et al.
Publicado: (2020)

Novel p53-dependent anticancer strategy by targeting iron signaling and BNIP3L-induced mitophagy
por: Wilfinger, Nastasia, et al.
Publicado: (2015)

Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer
por: Zhang, Shengliang, et al.
Publicado: (2022)

Activating p53 family member TAp63: A novel therapeutic strategy for targeting p53‐altered tumors
por: Gunaratne, Preethi H., et al.
Publicado: (2019)

Selective therapeutic strategy for p53-deficient cancer by targeting dysregulation in DNA repair
por: Zonneville, Justin, et al.
Publicado: (2021)

IKKbeta and p53 as therapeutic targets for arthritis
por: Tak, PP
Publicado: (2001)

Understanding and Therapeutic Targeting of the p53 Network
por: Bacher, Susanne, et al.
Publicado: (2023)

Role of p53 isoforms and aggregations in cancer
por: Kim, SeJin, et al.
Publicado: (2016)

RNA modulates aggregation of the recombinant mammalian prion protein by direct interaction
por: Kovachev, Petar Stefanov, et al.
Publicado: (2019)

p53-dependent and p53-independent anticancer effects of different histone deacetylase inhibitors
por: Sonnemann, J, et al.
Publicado: (2014)

Cytoplasmic p53 aggregates accumulated in p53-mutated cancer correlate with poor prognosis
por: Iwahashi, Naoyuki, et al.
Publicado: (2022)

Role of Sex in the Therapeutic Targeting of p53 Circuitry
por: Mancini, Francesca, et al.
Publicado: (2021)

p53 Isoforms as Cancer Biomarkers and Therapeutic Targets
por: Zhao, Liuqun, et al.
Publicado: (2022)

Treating p53 Mutant Aggregation-Associated Cancer
por: Kanapathipillai, Mathumai
Publicado: (2018)

Protein of a thousand faces: The tumor-suppressive and oncogenic responses of p53
por: Marques, Mayra A., et al.
Publicado: (2022)

A Novel Anticancer Therapy That Simultaneously Targets Aberrant p53 and Notch Activities in Tumors
por: Yao, Yuting, et al.
Publicado: (2012)

Targeting mitochondria as an anticancer strategy
por: Dong, Lanfeng, et al.
Publicado: (2019)

Therapeutic potential of ReACp53 targeting mutant p53 protein in CRPC
por: Zhang, Yaqun, et al.
Publicado: (2019)

Trojan Horse‐Like Nano‐AIE Aggregates Based on Homologous Targeting Strategy and Their Photodynamic Therapy in Anticancer Application
por: Li, Yin, et al.
Publicado: (2021)

p53 Modulation as a Therapeutic Strategy in Gastrointestinal Stromal Tumors
por: Henze, Joern, et al.
Publicado: (2012)

Targeting autophagy: a novel anticancer strategy with therapeutic implications for imatinib resistance
por: Carew, Jennifer S, et al.
Publicado: (2008)

Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies
por: Pistritto, Giuseppa, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_pmfqako30r8t06egfmjo8jl96s